Relationship between human chorionic gonadotropin serum levels and the risk of ovarian hyperstimulation syndrome

Gynecological Endocrinology

Volumn 30, Issue 4, 2014, Pages 294-297

  Johnson, Matrika D ^a   Williams, Sanithia L ^a   Seager, Christopher K ^a   Liu, James H ^a   Barker, Nichole M ^a   Hurd, William W ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chorionic gonadotropin; in vitro fertilization; Ovarian hyperstimulation syndrome

Indexed keywords

CHORIONIC GONADOTROPIN;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; OOCYTE; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; RISK FACTOR; BLOOD; COHORT ANALYSIS; ECHOGRAPHY; OVULATION INDUCTION; PROCEDURES; REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

ADULT; CHORIONIC GONADOTROPIN; COHORT STUDIES; FEMALE; FERTILIZATION IN VITRO; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84897908429     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.875998     Document Type: Article

References (19)

1. Luke B, Brown MB, Morbeck DE, et al. Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. Fertil Steril 2010;94: 1399-404.
2. Lee KH, Kim SH, Jee BC, et al. Comparison of clinical characteristics between early and late patterns in hospitalized patients with ovarian hyperstimulation syndrome. Fertil Steril 2010;93: 2274-80.
3. Asch RH, Li HP, Balmaceda JP, et al. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 1991;6: 1395-9.
4. Golan A, Ron-el R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44: 430-40.
5. The European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as; but safer than, urinary human chorionic gonadotropin in inducing final maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001;86: 2607-18.
6. Papanikolaou EG, Humaidan P, Polyzos NP, Tarlatzis B. Identification of the high-risk patient for ovarian hyperstimulation syndrome. Semin Reprod Med 2010;28: 458-62.
7. Al-Shawaf T, Grudzinskas JG. Prevention and treatment of ovarian hyperstimulation syndrome. Best Pract Res Clin Obstet Gynaecol 2003;17: 249-61.
8. Kashyap S, Parker K, Cedars MI, Rosenwaks Z. Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose. Semin Reprod Med 2010;28: 475-85.
9. Morris RS, Paulson RJ, Sauer MV, Lobo RA. Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum Reprod 1995;10: 811-4.
10. Shapiro BS, Daneshmand ST, Garner FC, et al. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization. Fertil Steril 2005;84: 93-8.
11. Driscoll GL, Tyler JP, Hangan JT, et al. A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod 2000;15: 1305-10.
12. The European Recombinant Human Chorionic Gonadotrophin Study Group. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment - recombinant HCG versus urinary HCG. Hum Reprod 2000;15: 1446-51.
13. Chang P, Kenley S, Burns T, et al. Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitrofertilization-embryo transfer. Fertil Steril 2001;76: 67-74.
14. Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril 2004;82: 841-6.
15. Asch R, Ivery G, Goldsman M. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum. Reprod 1993;8: 1015-20.
16. Mathur RS, Akande AV, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73: 901-7.
17. Demidenko E. Sample size determination for logistic regression revisited. Statistics Med 2007;26: 3385-97.
18. Detti L, Mohamed F, Mitwally M, et al. Serum human chorionic gonadotropin level after ovulation triggering is influenced by the patient's body mass index and the number of larger follicles. Fertil Steril 2007;88: 152-5.
19. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010;94: 389-400.